In ICON6, the use of cediranib, another oral angiokinase inhibitor that targets VEGFR and PDGFR, in addition to platinum-based chemotherapy for platinum sensitive, recurrent ovarian cancer showed a PFS benefit of almost three months (p < 0.0001) [21]. The gene discussed is KDR; the disease is ovarian cancer.